Table 1.
Demographic | Variable | Patients (n = 44) |
---|---|---|
Mean age ± SD (y) | 52.5 ± 10.6 | |
Mean tumor size ± SD (cm) | 4.6 ± 2.5 | |
Menopausal status | Premenopausal | 16 (36.4%) |
Postmenopausal | 28 (63.6%) | |
Initial diagnosis | Invasive breast cancer NOS | 1 (2.27%) |
Invasive ductal | 39 (88.63%) | |
Invasive lobular + mixed invasive and lobular | 4 (9.09%) | |
Estrogen receptor status | Positive | 24 (54.54%) |
Negative | 20 (45.45%) | |
Progesterone receptor status | Positive | 25 (56.81%) |
Negative | 29 (65.91%) | |
HER2 status | Positive | 12 (27.27%) |
Negative | 22 (50.00%) | |
Receptor status | Triple negative | 9 (20.45%) |
Other | 35 (79.54%) | |
Grade at diagnosis | 1 | 1 (2.27%) |
2 | 9 (20.45%) | |
3 | 27 (61.36%) |
Percentages not adding up to 100% are due to missing data; tumor size was determined using baseline imaging. HER2 = human epidermal growth factor receptor type 2. SD = standard deviation.